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1. Introduction 
Coeliac disease (CD) is a common autoimmune disorder that has genetic, environmental, 
and immunological components. Though under-diagnosed, it is one of the most prevalent 
chronic gastrointestinal diseases in humans, and exhibits unusually large clinical, 
histological, immunological, and genetic heterogeneity (Alaedini & Green, 2005; Sollid & 
Khosla, 2005). The clinical spectrum of CD has been expanded in recent years, with the 
identification of asymptomatic patients, patients with minimal symptoms (the most difficult 
to detect), and patients with extra-intestinal symptoms (Sollid & Khosla, 2005). Regardless of 
symptomatic presentation, the active disease in virtually all CD patients requires dietary 
exposure to a common environmental antigen, gluten. The ingestion of gluten proteins 
contained in wheat, barley, and rye, and in some cases oats (Arentz-Hansen et al., 2004; 
Comino et al., 2011), leads to characteristic inflammation, villous atrophy, and crypt 
hyperplasia in the CD patient’s upper small intestine.  
Gluten is a complex mixture of polypeptides. The main immunogenic peptides of gluten 
belong to a family of closely related proline- and glutamine-rich proteins called prolamines 
(15% proline and 35% glutamine residues). Gliadin, hordein, secalin, and avenin are the 
prolamines of wheat, barley, rye, and oats, respectively (Sollid & Khosla, 2005).  
CD is triggered by peptides that result from the fragmentation of prolamines, and are not 
digested by human proteases because the high proline and glutamine content prevents 
complete proteolysis by gastric and pancreatic enzymes, and long oligopeptides that are 
toxic to coeliac sprue patients build up in the small intestine (Sollid & Khosla, 2005). In vitro 
and in vivo studies in rats and humans have demonstrated that a 33-mer peptide from -
gliadin is not digestible by gastric, pancreatic, and intestinal brush-border membrane 
endoproteases (Shan et al., 2002). This and similar peptides have been identified as the 
principal contributors to gluten immunotoxicity.  
At present, treatment with a gluten-free diet (GFD) is the only available therapy for CD 
patients. However, it is not easy to maintain a diet with zero gluten content because gluten 
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contamination of food is commonplace (Collin et al., 2004). Even products specifically 
targeted at dietary treatment of CD may contain tiny amounts of gluten proteins, either 
because of the cross-contamination of originally gluten-free cereals during their milling, 
storage, and manipulation, or because of the presence of wheat starch as a major ingredient. 
Gluten is a common ingredient in the human diet; after sugar, it is perhaps the second most 
widespread food substance in Western civilization. Since about 10% of gluten seems to be 
made up of potentially toxic gliadin peptides (Sollid & Khosla, 2005), the characterization 
and quantification of the toxic peptides of the gluten in foodstuffs is crucial to avoid coeliac 
damage and enable monitoring of their enzymatic detoxification.  
2. Gluten testing 
2.1 Antibodies testing for gluten-free foods 
A standardized method of analysis is needed to quantitatively determine the gluten content 
of food and provide the basis for enforcing regulations regarding use of the term “gluten-
free” in food labelling. People with coeliac disease should feel confident that foods labelled 
"gluten-free" have been assessed for gluten using the same "best available" methodology. 
According to the Codex Alimentarius, only food with a gluten content under 20 ppm can be 
considered gluten-free. Food containing between 20 ppm and 100 ppm of gluten is 
considered to be very low in gluten content according to EU regulations, but there is no full 
agreement among countries about the term “gluten-free food”. Unfortunately, there is not a 
well-defined correlation between the amount of gluten ingested and the severity of clinical 
symptoms, which makes finding a threshold value difficult. Various antibodies (Ab) have 
been raised against different gliadin epitopes. The anti -gliadin Ab is used in a sandwich 
format that was approved as an official method by the AOAC (Association of Official 
Agricultural Chemists; Skerritt & Hill, 1991). However, the content of -gliadin in wheat 
varies significantly, from 6% to 20%, and this method cannot accurately detect and quantify 
barley prolamines (Thompson & Mendez, 2008). The -gliadin (Skerritt) ELISA was 
developed in 1991 and was considered a first reference assay. Subsequent assays have 
improved on some of the important limitations of the techniques based on the Skerritt 
antibody ELISA. Other antibodies were raised against different epitopes of -gliadin, such 
as PN3 (residues 31-49) for the toxic 19-mer peptides (Ellis et al., 1998), CDC5 (residues 56-
75; Nassef et al., 2008), Abs against T-cell stimulatory peptides present in gluten (Mitea et 
al., 2008), and R5, which recognized highly repeated peptide sequences present in wheat, 
barley, and rye grains (Valdés et al., 2003). The sandwich R5 ELISA was endorsed as a type I 
method by the Codex Committee on Methods of Analysis and Sampling (Codex Alimentarius 
Commission. Report of the 27th session of the Codex Committee on methods of analysis and sampling 
2006, ALINORM 06/29/23) for gluten determination. One criticism is that it overestimates 
barley hordein (Thompson & Méndez, 2008). It is also unable to accurately quantify 
hydrolyzed gluten.  
2.2 Antibodies to toxic gluten peptides 
Recent advances in the coeliac field strongly recommend updating the concept of “gluten 
detection” to “potential relative immunotoxicity of gluten” for the safety of coeliac 
consumers of food. Two monoclonal antibodies (moAbs), A1 and G12, were raised against 
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the immunodominant peptide 33-mer (LQLQPFPQPQLPYPQPQLPYPQPQLPYP QPQPF, 
residues 57 to 89; Morón et al., 2008a).  
2.2.1 Detection of gliadin immunogenic peptide by anti-33-mer moAbs 
The 33-mer peptide from -2 gliadin is a principal contributor to gluten immunotoxicity 
(Shan et al., 2002). Thus the production of moAbs against this toxic gluten peptide could be 
of great importance in both research and diagnosis. We obtained moAbs against the 33-mer 
peptide (A1 and G12 moAbs) (Morón et al., 2008a). To test the relative sensitivity of each 
moAb for the 33-mer peptide, we immobilized different concentrations of the C-LYTAG-33-
mer polypeptide, and detected with A1 and G12 moAbs in an indirect ELISA. The affinity of 
each moAb for the antigen was quantified by calculation of the concentration of the antigen 
giving a 50% reduction of the peak signal in the ELISA (IC50). The sensitivity of the G12 
moAb for the toxic 33-mer peptide was about eight times higher than that of A1 (Figure 1A). 
To test for moAb specificity, we studied the cross-reactivity (CR) values of these moAbs 
against commercial gliadin, also by indirect ELISA. The G12 moAb presented an IC50 of 
almost double that obtained with the A1 moAb, suggesting that A1 had broader reactivity 
with gliadin epitopes than did G12, which is more specific for the 33-mer (Figure 1B). 
 
Fig. 1. Standard curve of the detection of C-LYTAG-33-mer polypeptide (A) and Sigma 
gliadin (B) by indirect ELISA using G12 (black) and A1 (white) moAbs. Each point of the 
curve represents the mean ±standard deviation of n=4 assays. IC50 values of the moAbs to 
the two antigens are indicated. 
2.2.2 Characterization of A1 and G12 moAb sensitivity for coeliac-toxic cereals 
We investigated whether the G12/A1 moAbs were able to detect the presence of gliadin 33-
mer-related epitopes in prolamines from various cereals (Morón et al., 2008a; 2008b). To 
obtain quantitative data on the capacity of these antibodies to detect coeliac-toxic 
prolamines, we performed an indirect ELISA with samples of wheat, barley, rye, oats, rice, 
and maize (Figure 2). The assay proved to be highly specific for wheat, rye, and barley, as no 
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signal was observed in samples containing prolamines from rice or maize (Figure 2). The 
G12 and A1 moAbs detected oats with lower sensitivity, indicating that there are peptides in 
avenin with sequence similarity to the 33-mer. This is consistent with the identification of 
proline- and glutamine-rich epitopes in avenins that are toxic in some CD patients (Arentz-
Hansen et al., 2004). The lower sensitivity for oat avenins may be due to the lower 
proportion of oat-flour protein content consisting of prolamines relative to the proportion of 
gliadins, hordeins, or secalins in their respective grains. 
The A1 moAb was clearly more sensitive than the G12 moAb for the detection of the 
prolamine fractions from wheat, barley, rye, and oats. Although they were targeted at the 
toxic 33-mer peptide of wheat gliadin, both moAbs were more sensitive for barley than for 
wheat (Figure 2), with the affinity for barley of the A1 moAb being almost three-fold higher 
than that of the G12. The A1 was also more sensitive for the prolamines of rye than for those 
of wheat. 
 
Fig. 2. Comparative reactivity of prolamines from wheat, barley, rye, oats, maize, and rice 
from indirect ELISAs using G12 (black) and A1 (white) moAbs. Each point of the curve 
shows the mean of n=3 assays. IC50 and CR values of the moAbs to prolamines are 
indicated. N.A.: Not applicable. 
2.2.3 Development of a competitive ELISA assay using the anti-gliadin 33-mer moAbs 
The preparation of many foodstuffs involves heating or enzymatic processes that may 
partially hydrolyze or deamidate gluten. As a result, the quantity of gluten extracted from 
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foodstuffs processed by heat or fermentation may be underestimated by indirect or 
sandwich ELISA. We therefore developed a competitive ELISA method using the G12 
moAb. The result was a highly sensitive competitive assay with a limit of detection of 0.44 
ng/mL and a limit of quantification of 3.95 ng/mL. The gliadin concentration giving a 50% 
reduction in the maximum signal (i.e., IC50) in the standard curve of the competitive ELISA 
was determined to be 26.92 ng/mL. The repeatability and reproducibility of the method 
were calculated from various standard curves performed on the same ELISA plate (intra-
assay) and on different ELISA plates (inter-assay), respectively. For the standards situated 
between 25 ng gliadin/mL and 1.56 ng gliadin/mL, the intra-assay was 1.38–3.75%, and the 
inter-assay was 1.65–10.30% for the same standards. To determine whether the competitive 
assay was able to detect small fragments originated by gliadin digestion, we analyzed a 
sample of gliadin that had been digested with trypsin and pepsin. We observed that the 
developed assay could detect the peptides coming from the degradation of gliadin by these 
enzymes. We also analyzed a sample of hydrolyzed baby cereals in which the gliadin had 
been partially hydrolyzed during processing. These cereals contain a mixture of wheat, 
barley, rye, oat, and rice flours. The ethanolic extract obtained from the foodstuff was 
analyzed using the competitive ELISA. The partially hydrolyzed prolamines present in the 
sample were able to compete, and the quantitative assay could be performed. 
We developed a similar assay using the A1 moAb. The repeatability and reproducibility of 
the method were calculated from various standard curves performed on the same ELISA 
plate (intra-assay), and on different ELISA plates (inter-assay). The intra-assay coefficient of 
variation of the standards situated between 100 ng/mL of gliadin and 1.56 ng/mL of gliadin 
was found to be between 1.37% and 5.21%, while the inter-assay coefficient of variation was 
between 3.16% and 11.78% for the same standards. 
2.2.4 Analysis of the epitope recognition of G12 and A1 moAbs 
To determine the epitope recognized by the G12 and A1 moAbs within the 33-mer peptide, 
fusions of the C-LYTAG coding sequence of the pALEXb plasmid (Biomedal S.L., Seville, 
Spain) were constructed with coding sequences of hepta- and octapeptides comprising the 
complete sequence of the 33-mer peptide (Figure 3A). The resulting plasmids were 
introduced by transformation into the REG1 strain of Escherichia coli, allowing for 
overexpression of the encoded fusion proteins upon induction (Biomedal S.L., Seville, 
Spain). The overexpressed bacterial extracts were analyzed by indirect ELISA using the anti-
33-mer A1 and G12 moAbs. Similarly, the anti-C-LYTAG 6B5L1 moAb (Biomedal, S.L., 
Seville, Spain) was used to establish that the designed protein was expressed intact in all 
cases. A reference signal in the bacterial extract containing the C-LYTAG-33-mer fusion 
protein was observed for all the moAbs assayed (A1, G12, and 6B5L1) (Figure 3B). 
Saturating signals were obtained in the indirect ELISA analysis using the anti-C-LYTAG 
6B5L1 moAb for all the analyzed fusion proteins, indicating that all fusion proteins were 
overexpressed (Figure 3B). 
With regard to the determination of the sequence of recognition of the anti-33-mer moAbs 
(G12 and A1), a positive signal was detected only in the bacterial extracts containing the 
fusion peptides Pro63-Tyr69 (PQPQLPY) and Gln64-Pro70 (QPQLPYP) for the G12 moAb 
and in the bacterial extracts containing the fusion peptide Gln66-Pro72 (QLPYPQP) for the 
A1 moAb (Figure 3B). These results thus indicate that the region of recognition within the 
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33-mer peptide for the G12 moAb is QPQLPY (common to the fusion proteins Pro63-Tyr69 
and Gln64-Pro70) and that for the A1 moAb is QLPYPQP. 
 
Fig. 3. Analysis of anti-33-mer moAb recognition regions in recombinant 33-mer peptide 
fragments expressed in E. coli. A. Nucleotide sequences and the deduced amino acid 
sequences of the encoded peptide fusions to C-LYTAG. B. Detection of C-LYTAG-peptide 
fusions by an indirect ELISA with the use of G12, A1, and 6B5L1 moAbs. 
2.2.5 Study of the relative affinity of the G12 moAb for different peptide variants 
derived from the regions of recognition 
The recognition sequence of the G12 moAb (QPQLPY) is repeated three times within the 
gliadin 33-mer peptide. To determine the relative affinity of G12 for this epitope, and for 
similar sequences present elsewhere in toxic prolamines, we constructed hexapeptide 
variants of the G12 epitope, two of which were designed based on their presence in the 
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prolamines of barley and rye (Figure 4A and 4C). The affinity of the G12 moAb for different 
hexapeptide variants was determined in a competitive assay in which immobilized gliadin 
was challenged with QPQLPY-derivative peptides as soluble competitors (Figure 4A). The 
G12 moAb had high affinity for the peptide QPQLPF, reduced only four-fold relative to the 
previously identified epitope recognized by this moAb in the 33-mer, QPQLPY (Figure 4B). 
While the conservative replacement of tyrosine (QPQLPY) with phenylalanine (QPQLPF) 
did not drastically reduce the affinity of the G12 moAb, substitution with leucine (QPQLPL) 
reduced the affinity a thousand-fold, indicating the importance of this last position in 
determining affinity. A dramatic reduction in affinity was also observed for the peptide 
QPQQPY, with the affinity of the anti-33-mer G12 moAb decreasing as follows: 
QPQLPY>QPQLPF>>QPQLPL>QPQQPY. 
 
Fig. 4. Relative affinity of the G12 moAb for different peptide variants derived from its 
recognition region (QPQLPY). A. Amino acid sequences of the peptides. The G12 
recognition sequence in the 33-mer peptide is in bold face. IC50 and CR values of the G12 
moAb to peptides are indicated. B. Competition assay measuring the affinity of the G12 
moAb for the peptides. Two separate assays were performed with the antibody, each with 
three repetitions. C. Localization of the peptides in the-gliadin (accession number: 
JQ1047), c-secalin (accession number: ABO32294.1), and C-hordein (accession number: 
AAA92333.1) sequences. The same colour code for labelling the peptides has been used in A, 
B, and C. 
2.2.6 Determination of the peptide sequence preferences for A1 moAb binding 
We also studied the relative affinity of the A1 moAb for its recognition sequence 
(QLPYPQP) and for related peptide variants by a competitive assay (Figure 5A). The 
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peptides assayed for A1 were more numerous than those for G12 due to the longer 
heptapeptide recognition sequence contained in the 33-mer and to the suspected broader 
specificity of A1 for other prolamine sequences based on indirect ELISA assays (Figure 2). 
Figure 5 shows the affinity of the A1 moAb for the different peptides assayed; the IC50 was 
used to compare the affinity of A1 for each peptide.  
 
Fig. 5. Relative affinity of the A1 moAb for different peptide variants derived from its 
recognition region (QLPYPQP). A. Amino acid sequences of the peptides. The A1 
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recognition sequence in the 33-mer peptide is in red. B, C, D, and E. Competition assay for 
detection of the affinity of the A1 moAb for the peptides and their localization in -gliadin 
(B; accession number: JQ1047), c-secalin (C; accession number: ABO32294.1), C-hordein (D; 
accession number: AAA92333.1), and avenin (E; accession number: AAA32716.1). Two 
separate assays were performed with the moAb, each with three repetitions. IC50 values of 
the A1 moAb to peptides are indicated. N.A.: Not applicable. The colour code for labelling 
the peptides is the same as that used in A. 
Notably, two peptides present in secalin and hordein (QQPFPQP and QLPFPQP, Figures 5C 
and 5D, respectively) showed higher affinity for the A1 moAb than did the 33-mer-derived 
recognition sequence peptide (QLPYPQP). This suggests that the fourth residue in the 
recognition sequence is substantially important to A1 recognition, whereas the second 
position is not. Consistent with this, gliadin peptides QLPYPQP and QQPYPQP showed 
comparable affinity for the moAb (Figure 5B). The affinity of the anti-33-mer A1 moAb for 
epitopes present in coeliac-toxic cereals decreased as follows: 
QLPFPQP>QQPFPQP>QLPYPQP>QQPYPQP>>QQPYPQE.  
The affinity for the sequence included in the wheat gliadin 33-mer was not as high as for 
QQPFPQP, which is one of the most abundant sequences in secalin and hordein, similarly to 
the 33-mer epitope in gliadin. This may explain why, despite its lower affinity for the 33-mer 
peptide relative to the G12 moAb, the A1 moAb had a higher sensitivity for the whole range 
of toxic cereals tested in this study. The A1 moAb may therefore be useful as a sensitive 
detection tool for identifying coeliac-toxic peptides in complex foodstuffs. 
Preliminary attempts to find an avenin epitope gave no positive results (Figure 5E). The 
prolamines in oats represent much less of the total seed proteins than those in the other 
cereals. Furthermore, the amount of proline residues contained in avenins (10%) is about 
two-thirds that in the prolamines of wheat (gliadins and glutenins), barley (hordeins), and 
rye (secalins). In any case, we tested certain previously proposed potential avenin epitopes 
located in the avenin regions with the highest content of proline residues, regions also rich 
in glutamine, but could not obtain any reactivity to the A1 moAb. 
To study the relative importance of glutamine and proline residues in epitope selection by 
the A1 moAb, single substitutions or deletions were made to these amino acids in the 
recognition sequence (QLPYPQP). We performed the analysis with the A1 moAb rather than 
with the G12 moAb because A1 has higher sensitivity for prolamines from toxic cereals. 
When the first glutamine of the A1 recognition sequence was eliminated (LPYPQP), the 
affinity for A1 decreased significantly, consistent with the results from epitope scanning 
with the C-LYTAG fusions (Figure 3). Substitutions of each proline residue in the 
recognition sequence with a serine residue decreased A1 affinity markedly. This effect was 
greatest when the substitution was made in the second proline position (QLPYSQP), 
resulting in a CR that was practically zero. 
These results indicate that the initial glutamine residue and all three prolines of the epitope 
QLPYPQP were important for their recognition by A1, suggesting that this moAb could 
serve as a tool for monitoring enzymatic degradation of toxic peptides by potentially 
therapeutic glutamine- and proline-specific proteases. 
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2.2.7 Use of the A1 moAb to monitor gluten detoxification by candidate glutenases 
Oral administration of glutamine- and proline-specific proteases (i.e., glutenases) is a 
potential therapeutic alternative (or adjunct) to a gluten-free diet (Stepniak & Koning, 2006; 
Cerf-Bensussan et al., 2007). However, validation of the efficacy of these enzymes at 
detoxifying gluten in vitro must precede clinical testing, and such validation currently relies 
on low-throughput, technically challenging cell-culture-based assays (Siegel et al., 2006; 
Gass et al., 2007; Stepniak & Koning, 2006) or on polyclonal anti-gliadin-antibody-based 
ELISA assays that are only grossly quantitative (Gass et al., 2007). A competitive ELISA 
using an anti-33-mer moAb would enable high-throughput, highly quantitative testing of 
gluten detoxification by candidate therapeutic glutenases. 
We digested commercial whole-wheat bread under mock gastric conditions for 60 min with 
pepsin supplemented either with EP-B2 at varied concentrations (Figure 6A), or with a fixed 
EP-B2 concentration plus varied concentrations of SC PEP (Figure 6B). Dilution series of the 
quenched digests were prepared in parallel with a calibration dilution series of chemically 
synthesized 33-mer peptide, and these were tested against fixed 33-mer in an indirect 
competitive ELISA using A1 moAb. Treatment of whole-wheat bread with EP-B2 reduced 
the concentration of the 33-mer and close analogues by up to 10-fold in a dose-dependent 
manner (Figure 6A). This is consistent with the observation that EP-B2 cleaves the 33-mer 
after Gln66, Gln73, and Gln80 (Bethune et al., 2006), cleavages expected to extirpate the 
affinity of A1 for the resultant fragments.  
The combination of EP-B2 + SC PEP further reduced antigen concentrations by at least an 
additional 10-fold to levels undetectable by our methods (Figure 6B). This is again consistent 
with previously published results, in which EP-B2 substantially detoxified similar bread 
digests, but the synergistic combination of EP-B2 with SC PEP was required to dramatically 
reduce the intestinal T-cell reactivity of these digests (Gass et al., 2007). The intensity of the 
signal obtained with the A1 moAb in our assay was therefore proportional to the potential 
damage caused to a CD patient by a commercial gluten source (Morón et al., 2008b). 
2.2.8 Analysis of the recognition of anti-33-mer moAbs for deamidated and innate 
gluten peptides  
CD is closely associated with genes that code for human leukocyte antigens DQ2 and DQ8. 
These have been shown to bind with high affinity to gliadin-derived peptides in which 
specific glutamine residues in key positions have been converted to glutamic acid by 
transglutaminase-2-mediated deamidation (Alaedini & Green, 2005; Sollid & Khosla, 2005). 
A moAb capable of discriminating between native and deamidated gluten peptides would 
be a valuable research tool for monitoring the fate of digested prolamine peptides. To test 
the relative sensitivity of each moAb for the deamidated 33-mer peptide, a peptide 
(QPQLPYPQP) was designed that represented a region of recognition common to the two 
moAbs, together with the same peptide deamidated (QPELPYPQP).  
The affinities of the A1 and G12 moAbs for these peptides were determined by a 
competitive assay in which immobilized gliadin was challenged with peptides as 
competitors. The affinity of the G12 moAb for the deamidated peptide was about forty times 
higher than that of the A1 moAb. However, both moAbs recognized the non-deamidated 
peptide with >100-fold greater affinity than they did the deamidated peptide. In  
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Fig. 6. Indirect competitive ELISA using A1 moAb to test whole-wheat bread digests for 33-
mer content. A. Concentration of 33-mer (mg/mL) in whole-wheat bread digests containing 
0.6 mg/mL pepsin supplemented with specified concentrations of recombinant proEP-B2 
(U/mg gluten). B. Concentration of 33-mer (mg/mL) in whole-wheat bread digests 
containing 0.6 mg/mL pepsin and 32 U/mg EP-B2 supplemented with specified 
concentrations of recombinant SC PEP (U/mg gluten). The concentration of 33-mer in each 
digest was determined by comparison with a synthetic 33-mer standard curve. Two separate 
assays were performed with the antibody, each with three repetitions. 
combination with a previously characterized, commercially available moAb that has 20-fold 
greater affinity for the deamidated form of an overlapping gluten peptide than for its non-
deamidated counterpart, G12 and A1 moAbs may be useful for future studies on 
transglutaminase-2-mediated gluten peptide deamidation. 
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The innate immune response to gluten plays a key role in the development of CD (Fehniger 
& Caligiuri, 2001; Bernardo et al., 2007). This response is mediated by interleukin 15 (a 
typical cytokine of the innate immune system) and elicited by the toxic peptide p31-49 (19-
mer), derived from alpha-gliadin. To test whether the anti-33-mer A1 and G12 moAbs 
recognized peptide p31-49, competitive ELISAs with each moAb were performed. The A1 
moAb was able to detect p31-49 (IC50 3.18 mg/mL). The G12 moAb showed no affinity for 
the 19-mer peptide.  
These results were consistent with our previous identification of the QQPYPQP peptide, 
included in p31-49, as a permissive epitope for the A1 moAb. Therefore, this moAb shows 
an interesting range of peptide recognition that includes gliadin peptides involved in both 
the adaptive and the innate immunological responses in CD. 
3. The oats controversy: selection of oat varieties with no toxicity in coeliac 
disease 
There is an ongoing debate concerning the presence or absence of gluten in oats. 
Traditionally, treatment with a GFD has excluded not only wheat, barley, and rye, but also 
oats. Oats differ from other cereals in their prolamine content. The percentage of proline and 
glutamine (amino acids abundant in toxic regions) in avenin is lower than in other toxic 
cereals (Figure 8).  
Family 
Subfamily 
Tribe 
Genus 
Gramineae 
Bambusoideae Pooideae Panicoideae 
Tri ceae Aveneae Oryzeae Andropogonea Paniceae 
Tri ceae Secale Hordeum Avena Oryza Zea Sorghum Pennisetum 
Trigo Rye Barley Avena Arroz Maize Sorghum Millet 
WHEAT OAT RICE Basic characteris cs of prolamines 
>100 8‐25 34 (21 transcripts) Number of genes 
20‐40 kDa 19‐31 kDa 10‐16 kDa Molecular weight 
Gln (35%) 
Pro (25%) 
Gln (30%) 
Pro (10%) 
Gln (22%) 
Pro (<other cereals) 
Prevalence of amino acids 
40‐50% 10‐20% 25% Percentage of prolamines based on the 
total seed proteins 
Oat Rice Wheat 
A
B 
 
Fig. 8. Taxonomy and basic characteristics of the prolamines of oats in relation with other 
cereals. A. Taxonomy of oats in relation with other cereals. B. Basic characteristics of the 
prolamines of wheat, oats, and rice. 
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However, there is still some debate about the safety of oats (Pulido et al., 2009). Several in 
vivo and in vitro studies have indicated that the majority of coeliac subjects can tolerate 
moderate amounts of pure oats. Some countries permit the use of oats in “gluten-free” 
products, e.g. Gluten-Free Oats®. According to the Codex Standard for food for special 
dietary use for persons intolerant to gluten, CODEX STAN118-1979 (revised 2008, 
http://www.codexalimentarius.net/web/more_info.jsp?id_sta=291), oats can be tolerated 
by most, but not all, people who are gluten-intolerant. Therefore, the permitting of oats that 
are not contaminated with wheat, rye, or barley in foods covered by this standard may be 
determined at the national level. Moreover, according to the Commission Regulation (EC) 
No 41/2009 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:016:0003: 
0005:EN:PDF) concerning the composition and labelling of foodstuffs suitable for people 
intolerant to gluten, a major concern is the contamination of oats with wheat, rye, or barley 
that can occur during grain harvesting, transport, storage, and processing. Therefore, the 
risk of gluten contamination in products containing oats should be taken into consideration 
with regard to labelling of those products. Certain cross-reactivity with gliadin-specific 
antibody has been attributed to wheat contamination in oat-based food (Pulido et al.,  
2009). 
However, other authors shown clear evidence that avenins have the ability to induce the 
activation of mucosal T-cells, causing gut inflammation and villous atrophy (Pulido et al., 
2009). Arentz-Hansen et al. (2004) described the intestinal deterioration suffered by some 
CD patients following the consumption of oats while on GFD. Avenin can trigger an 
immunological response in these patients similar to the response produced by the gluten of 
wheat, rye, or barley. The monitoring of 19 adult coeliac patients who consumed 50 g/day 
of oats over twelve weeks showed that one of the subjects was sensitive to oats. Therefore, it 
is crucial to clarify either qualitatively or quantitatively the potential immunotoxicity of oats 
to coeliac patients (Arentz-Hansen et al., 2004; Pulido et al., 2009).  
In a previous work, we obtained two moAbs, G12 and A1, against the 33-mer peptide 
(Morón et al., 2008a). Our results suggested that the reactivity of these moAbs was 
correlated with the potential immunotoxicity of those dietary grains from which the 
proteins were extracted (Morón et al., 2008b; Ehren et al., 2009). These antibodies are able to 
recognize with great sensitivity peptides (besides the 33-mer peptide) immunotoxic for 
coeliac patients. The sensitivity and epitope preferences of these antibodies were found to be 
useful for detecting gluten-relevant peptides to infer the potential toxicity of food for coeliac 
patients. The G12 moAb showed cross-reactivity that served to detect a certain amount of 
oat avenins, although with lower sensitivity than the hordein, gliadin, and secalin (Morón et 
al., 2008a) The oats controversy appears to be a unique case for exploring this issue, because 
cases of intermediate immunotoxicity could be expected and the correlation of potential 
toxicity and analytical signal could be assessed.  
3.1 Relative affinity of the G12 moAb for different varieties of oats 
Different oat varieties monitored for their purity and by their distinct protein pattern 
(Figure 9), were used to examine differences in G12 moAb recognition by ELISA and 
Western blot. 
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Fig. 9. Comparison of avenin fractions extracted from oat varieties studied. Avenin spectra 
were determined by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry of the 9 oat varieties. Analysis of proteins extracted from the oat varieties by 
SDS-PAGE. MW: Protein molecular weight marker.  
To determine whether the G12 moAb had distinct reactivity to the different oat varieties, the 
affinity of the G12 moAb was determined by competitive ELISA. The G12 moAb showed 
different affinity for the oat varieties tested (Figure 10A). Therefore, three groups of oat 
varieties could be clearly distinguished depending on their recognition by the G12 moAb: a 
group of high affinity towards the antibody (OM719, OA729 and OE717), a group of 
intermediate recognition (OH727, OL715, and OC723), and another group comprising oats 
that were not recognized by the G12 moAb (OF720, OR721, and OP722). The alternative 
anti-33-mer A1 moAb provided equivalent results (data not shown). 
In order to quantify the affinity of the oat varieties for the G12 moAb, the IC50 and the CR 
were determined for each variety (Figure 10B). The IC50 is defined as the concentration that 
produces a reduction of 50% in the peak signal in the ELISA. The CR was determined as 
(IC50 of the oat variety that presents the greatest affinity for the antibody/IC50 of each 
variety assayed) x 100. Varieties OE717 and OA729 respectively showed a CR of around 60% 
and 75% with respect to the most sensitive variety (OM719). Varieties OH727, OL715, and 
OC723, with a CR of 25%, 24%, and 12%, respectively, were recognized by the G12 moAb, 
but with a lower sensitivity. The avenins of OF720, OR721, and OP722 were not recognized 
by the G12 moAb, as in the case of the negative control (rice).  
Sensitive Detection of Cereal Fractions that Are Toxic to Coeliac Disease  
Patients, Using Monoclonal Antibodies to a Main Immunogenic Gluten Peptide 
 
129 
In order to confirm the ELISA results with another immunological technique and to identify 
protein patterns with cross-reactivity to the anti-33-mer antibody, immunoblotting 
electrophoresis analyses were performed. The results (Figure 10C) showed that the G12 
moAb had affinity for the varieties OM719, OA729, OE717, OH727, OL715, and OC723. 
However, the antibody did not react with varieties OF720, OP722, and OR721. The 
variability in reactivity demonstrated by Western blot thus correlated with the previously 
presented ELISA results. These results suggested the presence of different prolamine 
subunits in the oat varieties, differing in both their amino acid composition and length.  
 
Fig. 10. Relative affinity of the G12 anti-33-mer moAb for different oat varieties and gliadin. 
A. Competitive ELISA using the G12-HRP anti-33-mer antibody to determine the relative 
affinity of this antibody against the different varieties of oats. Three assays were performed, 
with three replicates of each. Gliadin was used as positive control. B.  IC50 and CR of the 
different oat varieties. N.A.: Not applicable. C. Western blot analysis of toxic fractions from 
different prolamines extracted from the grains of oats. Membranes were stained with G12 
antibody. The colour code for labelling the varieties is the same as that used in A and B. 
3.2 Determining the concentration of immunoreactive peptides in oats 
To evaluate the relative amount of immunotoxic epitopes present in the prolamines of 
different oat varieties, one variety was chosen from each of the three groups previously 
identified for their affinity towards the G12 moAb. Thus, OM719 represented the group 
with greatest affinity towards the G12 moAb, OH727 those of intermediate reactivity, and 
OF720 those not recognized by this antibody.  
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The presence of immunoreactive peptides was determined by the G12 moAb competitive 
ELISA, using the 33-mer peptide as the standard curve. The presence of 33-mer and close 
analogues in the most reactive oat variety, OM719, was of the order of 1,340 ng/mg of 
avenin (Figure 11). In OH727, the levels of 33-mer were some 4-fold lower than in OM719. 
However, in the case of OF720, the concentration of 33-mer was reduced more than 1,300-
fold with respect to OM719, reaching levels undetectable by this method.  
This result was consistent with earlier results obtained using IC50 and CR, and by Western 
blot, and at the same time indicated the enormous difference between some varieties and 
others regarding the presence of sequences that are immunoreactive for coeliac patients.  
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Fig. 11. Detection of concentration of 33-mer peptide in different oat varieties. The 
concentration of 33-mer was determined by competitive ELISA using the G12 monoclonal 
antibody. Different dilutions were tested independently for each oat variety, each with three 
repetitions. 
3.3 Correlation between G12 moAb reactivity and immunogenicity of different oat 
varieties 
To determine whether the variations in the reactivity of the anti-33-mer G12 in the 
different oat varieties were correlated with the greater or lesser immunogenicity of the 
cereal, we directly challenged the cereal extracts with appropriate cells obtained from 
coeliac patients. The clinical and immunological characteristics of coeliac patients are 
presented in Table 1.  
Immunogenicity was determined by T-cell proliferation and IFN-γ production. Three 
cultivars of oats were selected -one variety was chosen from each previously identified 
group (OM719, OH727 and OF720). We tested whether there was a correlation between 
their potential immunotoxicity for coeliac patients and their reactivity with the G12 
moAb.  
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The avenin of the oat varieties, gliadin, and oryzein were subjected to peptic, trypsic, and 
chymotrypsin sequential digestion and treated with tTG. Cell proliferation and IFN- release 
in culture medium were measured as indices of lymphocyte activation.  
 
 
Patient 
 
Sex 
 
Age (years) 
 
Atrophy grade 
MARSH 
 
AAEM 
 
AATG 
 
 
HLA DQB1 
 
HLA DRB1 
Coeliac 1 Male 6 III b  + 252  0201-0202 3-7 
Coeliac 2 Female 3 III a + 20 0201-0202 3-7 
Coeliac 3 Male 13 III b - 2 0202-0301 7-11 
Coeliac 4 Female 5 III b + 102 0201-0604 3-11 
Coeliac 5 Female 9 III b + 139 0201-0202 3-7 
Coeliac 6 Female 2 III b + 15 0302-0301 4-4 
Coeliac 7 Female 4 III b + 28 0201-0501 1-3 
Coeliac 8 Female 7 II + 111 0201-0202 3-7 
Coeliac 9 Male 10 III b + 165 0202-0301 7-11 
Coeliac 10 Male 5 III b + 118 0201-0202 3-7 
Table 1. Clinical data of coeliac patients. AAEM: anti-endomysial antibody. AATG: anti-
transglutaminase antibody expressed U/mL. 
 
 
 
 
Fig. 12. Proliferative responses of T-cells to deamidated peptides of prolamine from three 
different oat varieties. PBMCs were exposed to tTG-treated prolamine-digest stimulation for 
48 h. Gliadin and oryzein were used as positive and negative control, respectively. The 
experiments were performed in duplicate, and the mean S.I. value ± SDM is shown. A. The 
S.I. values of T-cells exposed to prolamine digests were statistically significant with respect 
to the control (healthy patient) and B. with respect to oryzein. *p<0.05, **p<0.005.  
We found a significant increase of T-cell proliferation in cultures incubated with OM719 and 
gliadin (S.I.=1.3 ± 0.7 and 1.8 ± 0.9, respectively), and with OH727 (S.I.=1.02 ± 0.5). This 
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clearly showed that gliadin and OM719 displayed the highest activity, and were potentially 
the most immunogenic (Figure 12). The incubation with OF720 increased cell proliferation 
(S.I.=0.65 ± 0.4) similarly to that with oryzein (S.I.=0.62 ± 0.3). We included the values 
presented in healthy patients (control) as reference values to compare the effect of peptides 
in coeliac patients, under the same conditions of cell culture. Release of IFN- in the culture 
medium after the exposure of coeliac peripheral T-lymphocytes to deamidated avenin 
peptides was assessed (Figure 13). According to this assay, gliadin and prolamines from 
OM719 were very immunogenic, with the highest values of IFN- release (9.4 ± 0.76 pg/mL 
and 7.9 ± 0.57 pg/mL, respectively), while the exposure to OH727 induced a lower mean 
value of IFN- (4.8 ± 0.95 pg/mL). Finally, OF720 and oryzein were the least immunogenic 
(3.4 ± 1.09 pg/mL and 2.3 ± 0.89 pg/mL, respectively).  
 
 
 
 
 
 
Fig. 13 IFN- production by T-cells with prolamine digests from three different oat varieties. 
T-lymphocytes were stimulated with digested prolamines after treatment with tTG. IFN- 
production was evaluated by ELISA after 48 h of incubation. Results are shown as means of 
duplicate wells and expressed as pg/mL. Gliadin and oryzein were used as positive and 
negative control, respectively. A. Significant with respect to healthy control and B. with 
respect to oryzein. *p<0.05, **p<0.005. 
4. Conclusion 
Immunotoxic gluten peptides that are recalcitrant to degradation by digestive enzymes 
appear to trigger CD. A 33-mer peptide from -2 gliadin has been identified as a 
principal contributor to gluten immunotoxicity. A gluten-free diet is currently the only 
therapy for CD patients; therefore, the characterization and quantification of the toxic 
portion of gluten in foodstuffs is crucial to avoid coeliac damage. Our work was to 
develop tools for immunological assays to measure cereal fractions that are 
immunotoxic to CD patients. Two monoclonal antibodies, G12 and A1 (anti-33-mer 
antibodies), were developed against a highly immunotoxic gliadin 33-mer peptide. 
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Compared with other ELISAs, those based on these antibodies showed a broader 
specificity for prolamines that are toxic to CD patients, along with a higher degree of 
sensitivity, accuracy, and reproducibility. Furthermore, these antibodies have shown no 
cross-reactivity with any known food ingredient including soybean, as observed in the 
Codex standard R5 ELISA.  
Gliadin and other immunotoxic prolamines are sometimes hydrolyzed in food and drinks, 
which may result in the underestimation of the net amount of toxic fractions by other less-
specific antibodies that are not targeted at strictly immunotoxic peptides. The anti-33-mer 
antibodies have shown their practical efficacy as analytical tools in quantifying food toxicity 
for CD patients. These antibodies were assessed, and shown to be very suitable to provide a 
routine assay to determine gluten content, since their sensitivity and specificity were 
superior to previously described gluten immunoassays. Furthermore, the reactivity of these 
moAbs was correlated with the potential immunotoxicity of those dietary grains from which 
the proteins were extracted. T-cell reactivity analysis and enzymatic detoxification of the 
proteins showed that the signal of these antibodies was correlated with the sample’s 
potential toxicity for coeliac patients.  
We show, using the anti-33-mer antibodies raised against the toxic fragment, that oat 
immunogenicity for coeliac disease patients varies according to the variety of cultivar. 
We showed that the intensity of the signal obtained with the antibody was proportional 
to the potential damage caused to CD patients. We have proved that the reactivity of 
these antibodies with different varieties of oats was correlated with the immunotoxicity 
of those dietary grains from which the proteins were extracted, thereby providing a 
rational explanation of why some oats trigger immunological response, and a solution 
of how to avoid the presence of such varieties in gluten-free diets. The possibility of 
assessing the potential immunotoxicity to coeliac patients with a simple assay is an 
attractive idea with obvious applications in food analysis. Our study gives new insights 
about the dilemma of oats in coeliac disease, and suggests practical methods to select 
varieties of oats that are tolerable for coeliac patients, and at the same time, offers the 
possibility of measuring potential immunotoxicity by a simple immunological method, 
regardless of the cereal’s origin. The experimental design to resolve those issues served 
to shed light on an ongoing controversy regarding the contradictory conclusions from 
clinical studies to establish the tolerance of coeliac patients to oats. Our work should 
also be taken into consideration by food safety regulations - in particular, the labelling 
of gluten-free products that may contain oats. Therefore, this work may potentially 
have a social impact besides its relevance in basic and clinical research of coeliac 
disease.  
This work suggests considering whether the most practical way to measure food safety for 
coeliac patients is to quantify the amount of the immunoreactive prolamine epitopes, rather 
than the amount of any gluten in a given sample. The two antibodies have been used to 
develop different analytical techniques, including ELISA (competitive and sandwich) and 
immunochromatographic strips for routine assays (Glutentox®, Biomedal S.L., Seville, 
Spain). The A1- and G12-based immunoassays appear to be a promising approach to detect, 
with a direct relationship, any sample’s net toxicity for coeliac patients. 
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